Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.91
$0.126.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.58% | 8.67% | |||
| Total Other Revenue | 61.10% | -4.42% | |||
| Total Revenue | 5.34% | 8.21% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 5.34% | 8.21% | |||
| SG&A Expenses | -18.41% | 15.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.74% | 10.91% | |||
| Operating Income | -5.92% | -12.15% | |||
| Income Before Tax | -6.93% | -11.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.93% | -11.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.93% | -11.28% | |||
| EBIT | -5.92% | -12.15% | |||
| EBITDA | -1.53% | -19.06% | |||
| EPS Basic | -0.90% | 8.52% | |||
| Normalized Basic EPS | -0.96% | 8.50% | |||
| EPS Diluted | -5.41% | 9.19% | |||
| Normalized Diluted EPS | -0.96% | 8.50% | |||
| Average Basic Shares Outstanding | 5.90% | 21.72% | |||
| Average Diluted Shares Outstanding | 5.90% | 21.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||